Lantheus Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantheus Holdings, Inc. on January 29, 2025. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
On January 29, 2025, the Board of Directors appointed Phuong Khanh (P.K.) Morrow, M.D., as a new director. Key details of this change include:
- Board Size: Increased to eleven directors.
- Role: Appointed as a Class II Director with a term expiring at the 2026 annual meeting of stockholders.
- Committee Assignment: Member of the Science and Technology Committee.
- Independence: Determined to be an independent director under Nasdaq rules.
Compensation and Governance Details
Dr. Morrow's compensation package includes:
- Cash Compensation: $60,000 annually for Board service and $7,500 annually for Committee service (prorated for partial years).
- Initial Equity Grant: Valued at $100,000 (50% Restricted Stock Units, 50% Options), vesting in full on the first anniversary of the grant date.
- Annual Equity Grant: Commencing in 2025, valued at $400,000, vesting in full on the first anniversary of the grant date.
The filing states there are no family relationships between Dr. Morrow and other directors/officers, and no undisclosed material interests in transactions.
Investor Verification Checklist
- Verify Dr. Morrow's professional background and specific expertise in oncology clinical development.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Confirm the impact of the increased Board size on corporate governance dynamics.
- Monitor future filings for the vesting schedule execution of the initial and annual equity grants.